2. Signaling Pathways
  3. Immunology/Inflammation
  4. CD28
  5. CD28 Inhibitor

CD28 Inhibitor

CD28 Inhibitors (3):

Cat. No. Product Name Effect Purity
  • HY-P99302
    Lulizumab
    		Inhibitor
    Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling.
  • HY-P99961
    Tifcemalimab
    		Inhibitor
    Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer.
  • HY-P99293
    Galiximab
    		Inhibitor 99.23%
    Galiximab (IDEC 114) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody directed against the CD80 antigen and blocks CD80–CD28 binding. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma.